NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Astellas Pharma Inc
University of California, San Diego
Astellas Pharma Inc
Dartmouth-Hitchcock Medical Center
Eli Lilly and Company
Exelixis
Elevation Oncology
Institut Bergonié
Leap Therapeutics, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BioMed Valley Discoveries, Inc
NuCana plc
National Institutes of Health Clinical Center (CC)
Duke University
Palleon Pharmaceuticals, Inc.
Novartis
University of California, San Diego
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
Hoffmann-La Roche
Pfizer
Numab Therapeutics AG
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
BPGbio
Boston Scientific Corporation
Intensity Therapeutics, Inc.
Redx Pharma Ltd
Merck Sharp & Dohme LLC
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Tyme, Inc
AstraZeneca
Imunon
Servier
Novartis
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ethicon, Inc.
Genentech, Inc.
NantCell, Inc.
Federation Francophone de Cancerologie Digestive
Federation Francophone de Cancerologie Digestive
Theseus Pharmaceuticals
Kyowa Kirin Co., Ltd.
Exelixis